Cet anticorps Humanized Monoclonal détecte spécifiquement ErbB2/Her2 (Trastuzumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.
N° du produit ABIN7795082
Aperçu rapide pour Recombinant ErbB2/Her2 (Trastuzumab Biosimilar) anticorps (ABIN7795082)
Antigène
ErbB2/Her2 (Trastuzumab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Humanized
Clonalité
Monoclonal
Conjugué
Cet anticorp ErbB2/Her2 (Trastuzumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
Clone
4D5-8
Expression System
Mammalian cells
Fonction
Trastuzumab Biosimilar, Endotoxin 0.05 EU/mg
Attributs du produit
Trastuzumab, a humanized monoclonal antibody, interferes with the HER2/neu receptor and is mainly used to treat certain breast cancers, especially HER2-positive metastatic breast cancer. Combined with chemotherapy, trastuzumab increases both survival and response rate. There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1, HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, the HER receptors embedded in the cell membrane promote cell growth and division by turning genes on and off. The HER2 pathway stimulates cell proliferation if it normally functions, when HER2 is overexpressed, cell growth accelerates beyond its normal limits, which happens in some cancers, notably certain types of breast cancer.
Purification
Protein A or G affinity column
Pureté
>95 % by reducing SDS-PAGE
niveau d'endotoxine
Less than 0.5 EU/mg of protein as determined by LAL method